Future Health | March 02, 2021
Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited.
Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software.
Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”.
Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need.
Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”.
Future Health is an independent exhibition and conference organiser, based in London in the UK.
For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: firstname.lastname@example.org or to sign up to the Future Health platform, register at www.futurehealthinnovations.com
PocketHealth | June 18, 2022
Habersham Medical Center (HMC) announced that it will engage PocketHealth to help make it much easier for the hospital's 80,000 patients to access, share and store their medical imaging and reports securely on any device, enabling them to be more informed and active in their own healthcare journeys.
Patients will no longer need to travel to the healthcare facility to collect a CD-ROM of their records and transport it to their next appointment or hope that their critical health information makes it safely to their primary care physician. With PocketHealth, HMC's patients will be able to actively engage in their own healthcare journey by accessing and sharing their imaging reports with their physicians, caregivers, or family members from any device, anywhere in the world.
Physicians and other healthcare professionals who share and receive diagnostic images with Habersham will be able to work within the medical center's existing infrastructure and won't need to worry about additional software or account setup. They will be able to view patient imaging instantly in full diagnostic quality or import those images into their local PACS for diagnosis.
"We are very excited to make the healthcare experience much easier than it has been for patients at Habersham Medical Center, and in implementing PocketHealth at our hospital, we are equipping patients to be participants in their own medical journey. Until now, when medical imaging and reports were shared it required our patients to make unnecessary trips to the site.
Tyler Williams, President, and CEO of Habersham Medical Center
PocketHealth equips healthcare providers with the most efficient and effective way to share medical imaging while bringing patients into the center of the process, fueling better outcomes through direct access to diagnostic imaging and reports. Patients can now request all of their imaging records from HMC on the PocketHealth website and gain better insights into their reports with PocketHealth's Report Reader functionality, which breaks down and defines complex medical terms found within radiology reports.
"Diagnostic Imaging is essential to understanding a treatment course or for soliciting second opinions and can often be the spark for a long-term care journey," said Rishi Nayyar, co-founder and CEO, PocketHealth. "PocketHealth is thrilled to work with Habersham Medical Center to make it easy for patients and care providers to move through an image-based journey without the unnecessary frustration that often comes with records release and CD-ROM hardware."
Habersham Medical Center is focused on serving its communities by providing high quality healthcare to its patients and clinical partnerships. The Center conducts approximately 125,000 imaging exams each year.
PocketHealth is the world's first patient-centric image sharing platform. With PocketHealth, patients can instantly access, share and take ownership over their own medical imaging and records - anytime, anywhere, and with anyone. PocketHealth also enables direct sharing between hospitals and physicians, as well as instant DICOM retrieval and automated importing capability, creating a unified image management solution for more than 600 hospitals and imaging clinics across North America. PocketHealth believes that by placing patients at the center of their care journey, records move more ethically, easily and securely throughout the healthcare system.
About Habersham Medical Center
Serving over 80,000 residents across northeast Georgia, Habersham Medical Center (HMC) is a 53 licensed-bed, acute care hospital delivering exceptional care and service. As a substantial economic partner for Habersham County, HMC operates three physician practices, a comprehensive rehabilitation program, an 84 licensed-bed, skilled nursing home and the area's only hospital-based, home health service.
KLAS, Phreesia | May 30, 2022
KLAS, a healthcare research and insights firm, and Phreesia, a leader in patient intake, outreach and activation, are pleased to announce the release of a report that aims to shed light on patients’ preferences and expectations for the technology they interact with as a part of their healthcare experience. The report is the result of a survey designed to better understand patient sentiments on a range of topics, including how they like to schedule appointments, their participation in telehealth visits and their communication with their doctor.
KLAS and Phreesia partnered together on this report because they share a common mission of improving healthcare and the patient experience, and they recognize that patients’ voices and preferences are not always reflected in healthcare technology. The two organizations leveraged the size and scale of Phreesia’s network—which performed more than 100 million patient check-ins in 2021—to get a firsthand perspective of patients’ priorities.
"What do patients want?" asked Adam Gale, CEO of KLAS Research. "This report, based on a survey with nearly 13,000 patients, provides deep insights into how providers and vendors can help meet patient preferences."
Phreesia surveyed patients across the U.S. over a two-week period in 2021, as they checked in to a doctor’s appointment using Phreesia’s automated intake platform. The quantitative survey asked 14 questions about patients’ experiences using healthcare technology. Respondents represented a wide range of demographic groups across age, education level, race and gender.
The report includes many detailed, data-driven insights and recommendations to providers, including
Digital access tools are very important to patients: Online appointment self-scheduling and check-in, price transparency and online bill pay are among the offerings patients desire most. Survey responses indicate that patients aged 18-34 are almost twice as likely to choose organizations that have digital access tools.
There are gaps between what patients want and what is offered by vendors and provider organizations—for example, the ability to schedule and reschedule an appointment or request a prescription refill online.
Patients are still interested in telehealth: Nearly half of respondents had at least one virtual visit in the past year. Of those who did not, 40% reported they are likely to receive care virtually in the future.
Only 33% of respondents interact with a provider portal at least once a month, and 26% don’t use a portal at all, with the youngest patients (18-24 years old) most likely to fall into the latter category. The report recommends providers take a multi-pronged approach and offer technology alternatives for things like virtual care and patient communication to better engage those who rarely or never use a portal, in addition to encouraging increased portal adoption.
“As the report describes, patients want to be more actively involved in their healthcare, especially since the start of the pandemic. We believe that patient-centered care is critical to the transformation of our healthcare system. It’s incredibly important to us to be able to use our insights to help providers better engage patients and improve their experience. We’re thrilled to partner with KLAS on this valuable work.”
Phreesia CEO Chaim Indig
This collaboration is a result of Phreesia and KLAS’ common interest in ensuring patients’ voices are heard and that technology reflects their needs and preferences. As part of the non-financial agreement, KLAS performed its own analysis of Phreesia’s data, created this report and maintains editorial rights. KLAS’ partnership with Phreesia is in no way an endorsement of Phreesia’s performance and has had no impact on Phreesia’s standing in KLAS ratings.
KLAS has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996. The KLAS mission is to improve the world’s healthcare by amplifying the voice of providers and payers. The scope of our research is constantly expanding to best fit market needs as technology becomes increasingly sophisticated. KLAS finds the hard-to-get HIT data by building strong relationships with our payer and provider friends in the industry. Learn more at klasresearch.com.
Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency.
CeloNova BioSciences, Inc. | April 08, 2022
CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.
"We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies."
"I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices."
Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F
CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs.
"In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice."
Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1*
About CeloNova BioSciences, Inc.
CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.